Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 23Lymphoma 21Leukemia, Myeloid, Acute 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Myelodysplastic Syndromes 13Multiple Myeloma 13Breast Neoplasms 13Ovarian Neoplasms 11Lymphoma, Follicular 10Lymphoma, Mantle-Cell 9Leukemia, Lymphocytic, Chronic, B-Cell 9Leukemia, Biphenotypic, Acute 9Hodgkin Disease 9Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 8Sarcoma 7Waldenstrom Macroglobulinemia 6Burkitt Lymphoma 6Testicular Neoplasms 5Testicular Germ Cell Tumor 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Myelomonocytic, Chronic 5Carcinoma, Ovarian Epithelial 5Blast Crisis 5Myeloproliferative Disorders 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Congenital Abnormalities 4Central Nervous System Neoplasms 4

Interventions

ibrutinib 2fludarabine 2Sirolimus 2Rituximab 2Mycophenolic Acid 2Cyclophosphamide 2oblimersen 1Whole-Body Irradiation 1Surveys and Questionnaires 1Mesna 1KW-2478 1Hsp90 inhibitor KU757 1Filgrastim 1Busulfan 1Bortezomib 1Acupuncture Therapy 14-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Bronchiolitis Obliterans Syndrome × Filgrastim × Clear all
NCT04959175 2026-04-28

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
320 enrolled
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡